Table 2:

Toxicity comparison between 3 FDA-approved BRAFi + MEKi combinations. Vemurafenib and Combimetinib typically causes more skin toxicities. Dabrafenib and Trametinib have more fevers. Encorafenib and Binimetinib have more GI toxicities.

Combination	Most common toxicities	Less common toxicities	Dose Schedule
Vemurafenib + Cobimetinib	Rash, diarrhea, nausea, arthralgia, fatigue, photosensitivity, pyrexia, vomiting, serous retinopathy, alopecia and hyperkeratosis.	cuSCC, keratocanthoma, Bowen’s disease.	Orally, with or without food. Vemurafenib is twice daily every day. Cobimetinib is once daily on days 1–21.
Dabrafenib + Trametinib	Pyrexia, nausea, diarrhea, chills, fatigue, headache and vomiting.	Rash, palmer-plantar erythrodysesthesia, photosensitivity PPED, skin papillomas, cuSCC, keratocanthomas, hyperkeratosis.	Orally, on an empty stomach. Dabrafenib is twice daily. Trametinib is once daily.
Encorafenib + Binimetinib	Diarrhea, constipation, vomiting, abdominal pain, asymptomatic CPK increase, blurred vision.	Pruritis, hyerkeratosis, rash, keratosis pilaris, paloplatar keratoderma, palmer-plantar erythrodysesthesia, dry skin, skin papilloma, maculopapular rash, sunburn, alopecia, photosensitivity, arthralgia, myalgia, extremity pain, decreased appetite, musculoskeletal pain and decreased weight.	Orally, with or without food. Encorafenib is once daily and binimetinib is twice daily.